ABSTRACT Dopamine receptors were examined by Scatchard analysis in the striatal and olfactory tubercle regions of 11 inbred mouse strains. Simultaneous determinations ofthe binding characteristics of 3H-labeled 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN), a dopaminergic agonist, and
[3H]spiroperidol, a dopaminergic antagonist, were examined. Among the 11 strains, the equilibrium dissociation constant (kd for agonist binding did not vary in either the striatum or the olfactory tubercle. Similarly, no strain differences were observed in the Kd Despite intense investigative effort, the causes of the schizophrenic syndrome remain unknown. Both genetic and biochemical factors have been implicated. Hereditary factors are believed important in a high proportion ofcases ofchronic schizophrenia (1) , and a current neurochemical hypothesis is that this disorder may arise from hyperfunction of brain dopaminergic systems. In view of this, it is surprising that relatively little is known about the genetic control of dopamine in the brain. The brain possesses three principal dopaminergic systems. The mesolimbic-mesocortical system arises from cell bodies in the mesencephalon and is believed to be important in modulation of emotionality. The nigrostriatal system regulates extrapyramidal motor function. The tubero-infundibular system is important in neuroendocrine secretion. Within these systems, dopamine exerts its physiologic effects by interacting with receptors situated on pre-and postsynaptic neurons. Very little is known about the potential for genetic control of dopamine receptors or the degree to which abnormal behavioral, motor, or endocrine states are influenced by genetically determined variation in receptor properties. Reis et al. (2) and Baker et al. (3) have demonstrated strain differences in the number of neurons in dopaminergically innervated regions; these are associated with variations in behavioral responses to amphetamine.
The studies in this report were designed to investigate straindependent differences in brain dopamine receptors of inbred mice. To obtain a comprehensive overview ofpotential genetic variation, we measured dopaminergic receptors in the olfactory tubercle and corpus striatum of 11 inbred mouse strains. Receptor parameters were quantified by radioligand binding methods with 3H-labeled 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN), a high-affinity dopaminergic agonist, and [3H]spiroperidol, a potent dopamine antagonist. Simultaneous assays with these two ligands provide information about agonist and antagonist binding sites in the same preparation. This was done to determine ifobserved strain differences consisted predominantly of one or another type of binding site. The goals of the study were to determine whether strain differences in receptor affinity or concentration exist, whether observed strain differences were of comparable magnitude in the two dopaminergic regions, and whether a basis for determining the genetic transmission of receptor traits could be found. Table 1 shows the equilibrium dissociation constant (Ka) data from the strains tested. No significant interstrain differences in Kt were observed for either agonist or antogonist binding in either brain region. In the striatum, the K for spiroperidol varied among the strains from 6.5 to 7.1 X 10-11 M, whereas the Kd for ADTN ranged from 1.8 to 2.3 X 10-9 M. In the olfactory tubercle, the range of Kd for spiroperidol was from 8.6 to 9.4 Within most strains, the apparent Kd for spiroperidol was significantly lower in the striatum than in the olfactory tubercle. This difference in ligand affinity between the two dopaminergic regions has been described in other species (7) . It is of interest that it was observed only for spiroperidol and not for ADTN.
METHODS
Binding Site Concentrations. Although equilibrium binding constants did not vary between the strains tested, we observed dramatic differences in receptor binding-site concentrations ( peridol was 36-86 fmol/mg ofprotein and for ADTN was 2843. Analysis of variance disclosed highly significant strain differences for both agonist and antagonist binding sites in both brain regions.
Because strain differences existed in binding-site levels, it became of interest to determine the degree of association between agonist and antagonist binding sites. This was done by ran'king the strains for ADTN and spiroperidol binding in each brain region and testing for correlation by the Spearman method (6) . This analysis is summarized in Table 3 . There is a high positive correlation between the Bm, for ADTN Drug Competition Studies. The high correlation between ADTN and spiroperidol binding-site levels implies some degree of similarity or interdependence between these binding moieties. However, it has been reported that dopamine agonist and antagonist binding sites are pharmacologically distinct (8) . To clarify the nature ofbinding sites in the inbred mice, drug competition studies were carried out with compounds that compete with dopaminergic radioligands. These studies were conducted in four mouse strains selected for their potential suitability as progenitors in later breeding studies. The results of this study are shown in Table 4 . The data suggest the following major points:
(i) No strain differences in the concentration that inhibits maximal response by 50% (IC50) for displacing ADTN were seen for any drug in either the striatum or the olfactory tubercle. The four strains would appear to have qualitatively similar agonist binding sites.
(ii) No strain differences in IC50 for displacement of spiroperidol were seen for any drug in either the striatum or the olfactory tubercle.
(iii) Striatal spiroperidol binding sites differed from those in the olfactory tubercle. These regional differences in spiroper- Haloperidol and cyproheptadine both generated biphasic competition curves against [3H]spiroperidol in the olfactory tubercle and striatum (Fig. 2) . Further competition studies were undertaken to identify the types of binding sites involved in each phase of these curves. Two butyrophenone neuroleptics (clofluperol and aceperone) and two serotonin antagonists (mianserin and cinanserin) were used in these experiments.
Under normal conditions, competition with [3H]spiroperidol produces biphasic competition curves for these drugs similar to those generated by haloperidol and cyprcjkeptadine (Fig, 3A) . The data from the competition curves in Fig. 3 were used to estimate the percentage of dopamine and serotonin receptors in the striatum andolfactory tubercle relative to total [3H]spiroperidol binding. In both tissues dopamine and serotonin binding account for all of the [3Hlspiroperidol bound, which suggests that binding to a third receptor type is not significant. However, the presence of an intermediate concentration (150 nM) of haloperidol completely abolished the high-affinity component of the neuroleptic competition curves and the low-affinity component of the serotonin antagonist curves (Fig. 3B) . In contrast, 150 nM cyproheptadine abolished the high-affinity phase of cinanserin and mianserin competition and the low-affinity component of neuroleptic displacement (Fig. 3C) .
These results indicate that the high-affinity phase ofthe haloperidol competition curve represents inhibition of dopamine receptor binding, whereas the high-affinity component of the cypropheptadine curve reflects inhibition of serotonin receptor binding. Therefore, the degree of inhibition which occurs during the high-affinity components of haloperidol and cyproheptadine competition curves provides an indicator of the contributions of dopamine and serotonin receptors to total labeled spiroperidol binding. We used this approach to analyze the proportions of labeled spiroperidol binding in the same four strains analyzed in the earlier drug competition studies. These studies showed that 88-90% of the total striatal [3H]spiroperidol binding is to dopamine receptors, with the remaining fraction being serotonergic. There was very little interstrain variation in the percentage of striatal dopamine and serotonin receptors between the four strains ( Table 5) .
The olfactory tubercle presented quite a different picture. In this tissue only 53-66% ofthe total spiroperidol binding could be attributed to dopamine sites, with the remainder presumably being serotonergic. Considerably more variation in these percentages was observed in the olfactory tubercle compared to the striatum.
When the total [3H]spiroperidol binding is corrected for the proportion of dopamine sites in these four strains, the interstrain differences in dopamine receptors observed in Table 2 persist (Table 6) . Thus, these studies confirm the previous observations with ADTN that significant interstrain differences in dopamine receptors are seen in both the striatum and olfactory tubercle. They further suggest that similar differences exist in serotonin binding sites in these two tissues as well.
Sex Differences. To The high correlation between agonist and antagonist binding in both the olfactory tubercle and striatum, taken with the Scatchard data, would suggest the existence of a single type of receptor population to which both agonist and antagonist bind.
Subsequent investigation revealed this conclusion to be oversimplified and erroneous. Drug competition studies support the existence of a single type of ADTN binding site. This site is probably qualitatively similar in the olfactory tubercle and striatum but distinct from the spiroperidol binding site. Competition studies with drugs displacing spiroperidol show a complex pattern compatible with the existence of two types of spiroperidol binding site: The first of these has a high affinity for neuroleptics and a lower affinity for antiserotonergic drugs. These properties are similar to those described elsewhere (10) for the dopamine receptor. This receptor accounts for the great majority of [3H]spiroperidol binding in the striatum and about half ofthe binding in the olfactory tubercle. The second spiroperidol binding site has a high affinity for antiserotonergic drugs and a low affinity for neuroleptic drugs. It is present in low concentrations in the striatum but represents about half of the spiroperidol binding in the olfactory tubercle. The characteristics of this binding site are similar to those of the serotonin receptor described elsewhere (9) .
The lower affinity of neuroleptics for the serotonin/binding site may account for the higher binding constants found for
[3H]spiroperidol in the olfactory tubercle (Table 1 ). Under our assay conditions, it is possible that the presence of serotonin sites may skew Scatchard plots without introducing significant curvature. Because binding constants are estimated directly from the slope of the plot, a small but regular decrease in this slope could produce the changes in binding constants that we observed in Table 1 .
To the two possible neurotransmitter receptor types suggested above, we must add a further distinction based on binding data observed in male and female mice. Ourfindings suggest that differences in radioligand binding between sexes do not always occur, but when present they seem to be localized in the olfactory tubercle and can involve differences in both spiroperidol and ADTN binding (as in the C57L/J strain) or in spiroperidol binding alone (DBA/2J strain).
These studies indicate that strain differences in dopamine receptor binding exist, thus opening the possibility for study ofthe genetic controls on receptor binding. This study promises to be complex. Each binding site may be under genetic control and must be further characterized before genetic analysis can be undertaken. The lack of correlation between radioligand binding sites in the olfactory tubercle and striatum suggests that genetic controls on receptor binding operate independently in the two regions. If this is true, it has important clinical implications.
Genetic analysis also can be a powerful tool for analyzing the pharmacology of radioligand binding sites. During the course of breeding, the association of such phenotypic traits as ligand affinity and drug competition behavior can be examined. Receptor properties that cannot be distinguished in progenitor strains might be differentiated effectively through genetic analysis.
